https://www.selleckchem.com/products/azd5305.html
utility of resistin as a predictive biomarker in pediatric CD. Serum resistin levels at diagnosis of pediatric CD predict the escalation to biologic therapy at 12 months, independent of VAT volumes. Resistin and PAI-1 levels significantly improved in patients with CD after treatment using biologics compared with those not on biologics. These results suggest the utility of resistin as a predictive biomarker in pediatric CD.There is increased risk of cardiovascular disease in patients with chronic inflammatory disorders such as rheumatoid
Curtir
Comentario
Compartilhar
